A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Clinical trial NCT04995523 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04995523
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Small-Cell Lung Carcinoma

Start date: 2021-09-14
Primary completion: 2026-08-28
Enrollment: 212

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.